Dr. Chang is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
180 Harvester Dr
Ste 110
Burr Ridge, IL 60527Phone+1 773-834-4064Fax+1 773-834-7644
Summary
- Dr. Anthony Chang is a pathologist at the University of Chicago Medical Center. He received his medical degree from Albany Medical College and completed his pathology residency at the University of Washington and has been in practice for 16 years. He specializes in renal pathology.
Education & Training
- University of WashingtonFellowship, Renal Pathology, 2003 - 2004
- University of WashingtonResidency, Pathology-Anatomic and Clinical, 1999 - 2003
- Albany Medical CollegeClass of 1999
- Massachusetts Institute of TechnologyBS, Biology , 1991 - 1995
Certifications & Licensure
- IL State Medical License 2004 - 2026
- IN State Medical License 2024 - 2025
- American Board of Pathology Anatomic Pathology & Clinical Pathology
- American Board of PathologyAnatomic and Clinical Pathology
Awards, Honors, & Recognition
- Runner-up for best presentation by a resident in GI pathology Gastrointestinal Pathology Society, 2001
- Sheard-Sanford Award Finalist ASCP/CAP meeting, San Diego, Ca, 2000
Publications & Presentations
PubMed
- Androgens contribute to sex bias of autoimmunity in mice by T cell-intrinsic regulation of Ptpn22 phosphatase expression.Jean Lee, Leonid A Yurkovetskiy, Derek Reiman, Lara Frommer, Zoe Strong
Nature Communications. 2024-09-03 - Large lysosomes in Chédiak-Higashi syndrome.Wenyan Zhou, Jerome C Lane, Anthony Chang
Kidney International. 2024-08-01 - 1 citationsMicrobial influences on severity and sex bias of systemic autoimmunity.Jean Lee, Derek Reiman, Samara Singh, Anthony Chang, Laurence Morel
Immunological Reviews. 2024-08-01
Journal Articles
- Lineage-specific Identification of Non-Hematopoietic Neoplasms by Flow Cytometry.Chang A, Benda PM, Wood BL, Kussick SJ, Am J Clin Pathol
- Inflammatory Leiomyosarcoma: A series of 3 cases with additional insights into this very rare entity.Chang A, Schuetze SM, Conrad EU, Swisshelm KL, Norwood TH, Rubin BP, Int J Surg Pathol
- Four-Color Flow Cytometry Shows Strong Concordance with Bone Marrow Morphology and Cytogenetics in the Evaluation of Myelodysplasia.Kussick SJ, Fromm J, Rossini A, Li Y, Chang A, Norwood TH, Wood BL, Am J Clin Pathol
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- Bile casts in the kidney: a clinicopathologic study of 18 autopsies.Salem F, Meehan SM, Taxy JB, Chang A, Mod Pathol
- Clear cell cysts represent the earliest neoplastic lesion of renal cell carcinoma in acquired cystic disease patients.Hosseini M, Antic T, Taxy JB, Chang A, Mod Pathol
- ALH amyloidosis.Kim L, Meehan SM, Chang A, Mod Pathol
- Join now to see all
Other
- Protocol for the examination of specimens from patients with invasive carcinoma of renal tubular origin.Srigley JR, Amin MB, Delahunt B, Campbell S, Chang A, Grignon DJ, Humphrey PA, Leibovich B, Montironi R, Renshaw AA, Reuter VE
http://www.cap.org/apps/docs/committees/cancer/cancer_protocols/2012/Kidney_12protocol_3101.pdf - Protocol for the examination of specimens from patients with carcinoma of the renal pelvis and ureter.Humphrey PA, Amin MB, Srigley JR, Chang A, Cohen AH, Delahunt B, Epstein JI, Grignon DJ, Montironi R, Renshaw AA, Reuter VE
http://www.cap.org/apps/docs/committees/cancer/cancer_protocols/2012/RenalPelvUreter_12protocol_3200
Press Mentions
- Kidney Week 2019November 4th, 2019
- Kidney Biopsy of the Month: What Is Normal?January 4th, 2019
- 2016 Pre-Meeting MaterialsMarch 11th, 2016
Professional Memberships
- Fellow
- Member
- Fellow
- Member
- Renal Pathology SocietyPast-President
- Chicago Pathology SocietyPast-President
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: